The Numbers Behind the Frustration

In a 2023 mystery-shopper study published in General Hospital Psychiatry, researchers called 948 psychiatrists across five states posing as new patients. Fewer than one in five — 18.5% — were available to see a new patient at all. The most common reason was the simplest one: the practice was not taking new patients, full stop. For callers who did find an open door, the median wait was 67 days for an in-person appointment and 43 days for telepsychiatry.¹

For context, the average wait for a new-patient appointment across other medical specialties is 26 days.² Psychiatry is not a little slower than the rest of medicine. It is two and a half times slower — for conditions where motivation itself is a symptom.

What the Gap Actually Costs

• Readiness decays. The client who said yes in your office was at a motivational peak. Ambivalence reasserts itself within weeks — especially in the avoidant, the anxious, and the executively challenged, which is to say, the clients who most needed the referral.
• Symptoms compound. Two months of untreated escalation can mean a lost semester, a job in jeopardy, a marriage further eroded — outcomes a timely evaluation existed to prevent.
• The therapy stalls with them. You spend sessions managing the holding pattern instead of doing the work. The treatment plan is hostage to someone else’s calendar.
• Trust takes the hit. You recommended this. When the system fails to deliver it, some of that failure lands — unfairly but inevitably — on the recommendation, and on you.

What to Tell Clients While They Wait — and How to Shorten It

Why the Two Get Tangled

Both conditions produce inattention, but by different routes. Anxiety hijacks attention: the client cannot concentrate because their cognitive bandwidth is consumed by worry, threat-scanning, and rehearsal. ADHD fails to deploy attention: the client cannot concentrate because the regulation system itself is inconsistent — including when they are calm, including for things they care about. The downstream behavior looks identical in a fifty-minute session. The history rarely does.

And frequently the question is not either/or. In the National Comorbidity Survey Replication, nearly half of adults with ADHD also met criteria for an anxiety disorder.¹ Some of that anxiety is independent. Some of it is secondary — the accumulated dread of a life spent missing deadlines, losing keys, and disappointing people for reasons the client could never quite name. Treat only the anxiety in those clients and you are bailing water without patching the hull.

Questions That Sharpen the Differential

• Timeline. “Tell me about fourth grade.” ADHD is neurodevelopmental; the trail runs back to childhood, even when it was never named. Anxiety more often has an onset, a context, a before-and-after.
• Attention in calm waters. “When you’re relaxed and reading something you chose — what happens?” The anxious client can often sink in; the ADHD client drifts even on vacation.
• The flavor of restlessness. Anxious restlessness is driven by dread and quiets when the threat resolves. ADHD restlessness is constitutional — it is there on good days too.
• What worry is doing. Anxious clients worry ahead of events; ADHD clients are more often ambushed by them. “I knew it was due and couldn’t make myself start” is a different sentence from “I couldn’t stop thinking about it going wrong.”
• Response to structure. External scaffolding, like deadlines, body-doubling, accountability, often transforms ADHD performance. It soothes anxiety much less.

Raising the Possibility With a Client

The frustrating part is that we know coordination works. This post lays out what the evidence shows, what real collaboration looks like in practice, and the questions worth asking any psychiatrist before you send them your clients.

The Evidence: Teams Beat Silos

The best-studied model is collaborative care for depression in primary care. In the IMPACT randomized trial — 1,801 patients across 18 clinics — team-based care, in which a psychiatrist, care manager, and treating clinician actually communicated about shared patients, produced a response rate of roughly 45% at twelve months. Usual care produced 19%.¹ Same patients, same medications available, same evidence base. The difference was the structure: someone owned the follow-up, and the clinicians talked to each other.

Therapy-psychiatry collaboration is a different setting, but the mechanism transfers: shared patients do better when their clinicians operate as a team rather than as two strangers who happen to bill the same person.

What Real Collaboration Looks Like

• A closed loop after the first visit. With the client’s consent, you should hear that the appointment happened, what the working impression is, and what was started or changed. Silence after a referral is not neutrality; it is a coordination failure.
• Medication changes you hear about from the psychiatrist, not the client. You are watching the client weekly. If a dose changed, you are the early-warning system for both benefit and side effects — but only if you know.
• A reachable human. When you observe something concerning — activation, sedation, a mood shift — you need a channel that answers within a day or two, not a portal message into the dark.
• Respect for role boundaries in both directions. The psychiatrist does not restructure the therapy; you do not adjust the medication. Each of you knows what the other is doing and why.

Questions to Ask Before You Refer

This post offers language that works, language that backfires, and a way to handle the most common objections without turning the session into a debate.

Why the Framing Matters More Than the Facts

Clients rarely object to medication on the evidence. They object to what they believe a referral means about them: that they are broken, that their effort did not count, that their therapist is giving up on them. If the framing does not address those meanings directly, no amount of outcome data will move the conversation. Three frames consistently keep the therapy central:

• Information, not commitment. An evaluation is a conversation with a physician — an hour of expert input on a question you and your client have been circling for months. The client decides nothing today except whether they want more information.
• Augmentation, not replacement. The evidence backs this framing literally. In the NIMH MTA study, combined treatment doubled the success rate of behavioral treatment alone — 68% versus 34%.¹ Medication did not replace the behavioral work; it made the behavioral work land.
• Team, not handoff. The single most reassuring sentence you can say is some version of: “I am not going anywhere.” Clients fear losing you more than they fear the appointment.

Language That Works

Deciding when to raise a psychiatric referral is one of the harder judgment calls in outpatient practice. Refer too quickly and you risk medicalizing a problem the client could work through. Wait too long and your client spends months white-knuckling symptoms that a thoughtful medication evaluation might have eased. This post offers a practical framework for spotting the signals, raising the conversation, and choosing a psychiatric partner who will support your work rather than complicate it.

Signals That Stalled Progress May Have a Biological Component

No single sign is decisive, but when several of these cluster together, a psychiatric evaluation is worth considering:

• Skills that won’t deploy. Your client can describe their coping strategies perfectly in session but cannot access them in the moment. When baseline anxiety is high enough, the physiological alarm overrides everything you have built together. Medication can lower that floor so the skills finally have room to work.
• Attention symptoms interfering with the therapy itself. The client loses the thread mid-session, forgets homework not from avoidance but from genuine working-memory failure, or has a lifelong pattern of starting strong and trailing off — in jobs, relationships, and now in treatment. With roughly 4.4% of adults meeting criteria for ADHD and most cases going untreated,³ ADHD quietly undermines therapy more often than it gets credit for.
• Vegetative symptoms. Persistent sleep disruption, appetite change, or a fatigue that rest does not touch. These respond unevenly to psychological intervention alone.
• A true plateau despite a strong alliance. Good rapport, good adherence, an approach that fits the presentation — and yet the symptom severity has not budged in months. That pattern deserves a second set of eyes.
• Family history. A first-degree relative who responded well to medication raises the likelihood your client will too.

Raising It Without Undermining the Work

Many clients hear “maybe you should see a psychiatrist” as “therapy failed” or, worse, “you failed.” The framing that works best positions medication as something that serves the therapy, not something that replaces it:

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. Please consult a licensed healthcare provider for diagnosis and treatment. In a mental health crisis, call or text 988.

It’s Not Just a Childhood Condition

For decades, ADHD was considered something children outgrow. Research has definitively disproven that. ADHD is a lifelong neurodevelopmental condition — and for more than half of diagnosed adults, the diagnosis didn’t come until adulthood. Many spent years struggling with focus, organization, and emotional regulation without ever understanding why.

The gap between prevalence and care is striking: over one in three adults with ADHD receives no treatment at all — not medication, not therapy, nothing. Understanding the condition is the first step toward closing that gap.

What Is Adult ADHD?

Attention-Deficit/Hyperactivity Disorder (ADHD) is characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning. The DSM-5-TR recognizes three presentations:

• Predominantly Inattentive — difficulty sustaining focus, organizing tasks, and following through; often mistaken for laziness or apathy
• Predominantly Hyperactive-Impulsive — restlessness, acting without thinking, talking excessively; less common as a standalone type in adults
• Combined Presentation — meets criteria for both; the most commonly diagnosed in adults

In adults, ADHD looks different than the stereotype of a hyperactive child. Adults are more likely to experience internal restlessness — chronic disorganization, emotional reactivity, difficulty with time management, and an inability to complete tasks despite genuine effort and intelligence.

Why ADHD Gets Missed in Adults

Several factors contribute to delayed or missed diagnosis in adults. Girls and women are significantly underdiagnosed — their symptoms tend to present as inattentiveness rather than disruptive hyperactivity, making them easier to overlook. High-functioning individuals often develop compensatory strategies that mask impairment until demands become overwhelming — a new job, parenthood, or major life stress can unmask ADHD that was previously managed.

Co-occurring conditions further complicate the picture. Anxiety, depression, and substance use disorders are highly prevalent in adults with ADHD, and their symptoms can overshadow the underlying attention issues, leading to misdiagnosis and ineffective treatment.

Key distinction: ADHD is not a deficit of attention — it’s inconsistent regulation of attention. People with ADHD can hyperfocus intensely on highly engaging topics while struggling to sustain attention on tasks they find routine or low-stimulation.

Medical Disclaimer: This article is for educational purposes only. If you have concerns about your child’s development, please consult a qualified developmental or psychiatric specialist. Do not delay seeking evaluation based on this content alone.

What Is Autism Spectrum Disorder?

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition that affects how a child communicates, interacts with others, and experiences the world. Defined by the DSM-5-TR, ASD is characterized by persistent differences in social communication and interaction, paired with restricted or repetitive patterns of behavior, interests, or activities.

The latest CDC data (April 2025) identifies ASD in 1 in 31 eight-year-olds in the United States — up from 1 in 150 roughly two decades ago. This increase reflects broader diagnostic criteria, improved screening, and greater awareness, not a true epidemic. Diagnosis rates among Black, Hispanic, and Asian children now approach those of white children for the first time — a meaningful step toward equity.

Early Signs: What to Watch For

Signs of autism can be visible as early as 12 months, and reliable diagnosis is possible by 18–24 months. Yet the average age of first diagnosis remains around 4 years — a gap that represents missed early intervention. Common early signs include:

• Limited or inconsistent eye contact
• No response to name by 12 months
• Limited joint attention — pointing, showing, sharing interest
• Delayed or absent speech and language milestones
• Repetitive movements (hand-flapping, rocking, spinning objects)
• Rigid adherence to routines; strong distress with change
• Unusual or intense sensory sensitivities
• Highly focused, narrow interests

How Autism Is Diagnosed

There is no blood test or imaging study for autism. Diagnosis is clinical, based on a comprehensive developmental history, structured behavioral observation, and standardized assessment tools (such as the ADOS-2). A multidisciplinary team — including a developmental pediatrician, psychologist, and/or child psychiatrist — provides the most thorough evaluation.

Co-occurring conditions are the rule, not the exception. ADHD, anxiety, sleep disorders, gastrointestinal problems, and sensory processing differences are all common and require their own assessment and management.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice or a recommendation for any specific genetic test. Discuss whether pharmacogenomic or other genetic testing is appropriate for your care with a qualified psychiatric provider.

What Is Psychiatric Genetic Testing?

Genetic testing in psychiatry refers to laboratory-based analysis of a patient’s DNA to inform clinical decision-making. The most clinically utilized form today is pharmacogenomics (PGx) — testing that examines how genetic variants affect the way a person metabolizes, responds to, or tolerates psychiatric medications. A growing but still-emerging application is neuropsychiatric genetic panels, which screen for variants associated with conditions like ASD, ADHD, intellectual disability, and epilepsy.

This is one of the fastest-evolving areas in all of medicine. Understanding what these tests can — and cannot — do is essential for patients and families navigating psychiatric care.

How Pharmacogenomics Works

Most psychiatric medications are metabolized by enzymes in the liver, primarily from the cytochrome P450 (CYP450) family — including CYP2D6, CYP2C19, CYP3A4, and others. Genetic variants in these enzymes determine whether a person is a:

• Poor metabolizer — the enzyme functions slowly or not at all; standard doses may accumulate to toxic levels
• Intermediate metabolizer — reduced enzyme activity; may need lower doses
• Normal (extensive) metabolizer — expected response to standard doses
• Ultrarapid metabolizer — enzyme works faster than normal; standard doses may be ineffective as the drug is cleared too quickly

Commonly tested genes include CYP2D6 (affects metabolism of many antidepressants and antipsychotics), CYP2C19 (SSRIs like citalopram and escitalopram), and SLC6A4 (serotonin transporter gene, linked to SSRI response). The MTHFR gene variant — which affects folate metabolism and neurotransmitter synthesis — is also frequently included and has implications for treatment-resistant depression.

Clinically Recognized Applications

Medication Selection

When multiple medications are options, PGx results can help prioritize those likely to be metabolized normally and flag those with elevated risk of toxicity or subtherapeutic levels due to your metabolizer status.

Dose Optimization

Poor and ultrarapid metabolizers may require significantly different doses than standard guidelines suggest. PGx can guide dose adjustments before — not after — a trial-and-error period.

Treatment-Resistant Cases

When patients have failed multiple adequate medication trials, genetic testing may uncover metabolic explanations — such as ultrarapid CYP2D6 status — that were never previously considered.

Neurodevelopmental Evaluation

Chromosomal microarray and targeted gene panels are a standard part of evaluation for children with ASD, intellectual disability, or developmental delay — identifying clinically actionable variants in roughly 15–20% of cases.

Medical Disclaimer: This article is for educational purposes only and does not constitute medical advice. It does not replace a consultation with a licensed healthcare provider. If you are experiencing a mental health crisis, call or text 988 (Suicide & Crisis Lifeline) or go to your nearest emergency room.

The Magnesium–Mental Health Connection

Most people think of magnesium as a supplement for sleep or muscle cramps. But researchers and clinicians increasingly recognize its role in brain chemistry, stress regulation, and mood. Magnesium is involved in over 300 enzymatic reactions in the body — many of them directly tied to how we think, feel, and respond to stress.

Despite its importance, studies suggest that a significant portion of Americans do not get adequate magnesium from diet alone. Low magnesium levels have been associated with elevated anxiety, depressive symptoms, poor sleep, and even heightened sensitivity to stress. Understanding this connection can be a powerful complement to a comprehensive mental health care plan.

How Magnesium Affects the Brain

Magnesium regulates the activity of NMDA receptors — a type of glutamate receptor central to learning, memory, and mood. It acts like a natural “gatekeeper,” preventing excessive neuronal excitation that can contribute to anxiety and depression. When magnesium levels are low, this gating function weakens, and the nervous system can become overactive and dysregulated.

Magnesium also plays a role in:

• HPA axis regulation — the body’s stress response system. Low magnesium is linked to heightened cortisol release.
• Serotonin synthesis — the neurotransmitter associated with mood stability and well-being.
• Sleep architecture — supporting deeper, more restorative sleep through its calming effect on the nervous system.
• Inflammation — chronic low-grade inflammation is increasingly tied to depression, and magnesium has anti-inflammatory properties.

Magnesium and Depression

Several clinical studies have found associations between low dietary magnesium and higher rates of depression. A 2017 randomized controlled trial published in PLOS ONE found that supplementation with magnesium chloride led to significant improvements in depression and anxiety symptoms in adults with mild to moderate depression — with benefits appearing in as few as two weeks.

While magnesium is not a replacement for antidepressants or psychotherapy, it may serve as a meaningful adjunct — particularly for individuals who are deficient or whose diets are low in magnesium-rich foods like leafy greens, nuts, seeds, and whole grains.

Medical Disclaimer: This article is for educational purposes only. Supplements are not FDA-regulated medications and are not substitutes for evidence-based psychiatric treatment. Always discuss supplements with your prescriber before starting — interactions with psychiatric medications can occur.

Why Supplements Come Up in Psychiatry

More patients ask about supplements than ever before — for mood, focus, sleep, and anxiety. The honest answer: some have meaningful evidence behind them, others have very little, and almost none should replace established treatments. What they can do, in the right context, is complement standard care. Here is an evidence-informed look at the most commonly discussed supplements in psychiatric practice.

Supplements at a Glance

Omega-3 Fatty Acids (EPA & DHA) — Strong Evidence

EPA-predominant formulations (≥60% EPA, 1–2 g/day) have shown consistent benefit as adjuncts to antidepressants across multiple meta-analyses. Preliminary evidence also supports benefits in bipolar depression and ADHD. Fish oil is the most common form; algal oil provides DHA but less EPA. GI side effects are the main complaint.

Best studied for: Depression (adjunct), ADHD

Vitamin D — Moderate Evidence

Vitamin D receptors are found throughout the brain, and deficiency is extremely common — particularly in northern latitudes, older adults, and people with darker skin. Correcting a documented deficiency often improves energy and mood. Evidence for benefit in non-deficient individuals is mixed. Check a 25-OH vitamin D level; supplement with D3 if below 30 ng/mL (typical dose: 1,000–5,000 IU/day).

Best studied for: SAD, deficiency-related mood changes

Magnesium — Moderate Evidence

Magnesium is involved in over 300 enzymatic reactions including NMDA receptor regulation, cortisol modulation, and serotonin synthesis. Low levels are associated with anxiety, depression, and poor sleep. A 2017 RCT found significant improvement in depression and anxiety with magnesium chloride supplementation. Glycinate and threonate are better-tolerated forms. Typical dose: 200–400 mg elemental magnesium daily.

Best studied for: Anxiety, depression (adjunct), sleep

Probiotics & the Gut–Brain Axis — Emerging Evidence

Approximately 90% of serotonin is produced in the gut, and the gut microbiome communicates directly with the brain via the vagus nerve. Several RCTs suggest multi-strain probiotics may reduce anxiety and depressive symptoms. This is one of the most actively researched areas in psychiatry. Results are promising but not yet sufficient to recommend as a primary treatment.

Best studied for: Anxiety reduction, IBS-related mood symptoms

L-Methylfolate — Strong Evidence

L-methylfolate is the bioavailable form of folate that crosses the blood-brain barrier. It is involved in neurotransmitter synthesis (serotonin, dopamine, norepinephrine). In patients with the MTHFR gene variant who metabolize folate poorly, standard antidepressants may underperform. L-methylfolate (7.5–15 mg/day) is FDA-cleared as a medical food adjunct for depression. This is one of the most clinically useful nutraceuticals in psychiatry.

Best studied for: Treatment-resistant depression (adjunct)

NAC (N-Acetylcysteine) — Moderate Evidence

NAC is a precursor to glutathione, the brain’s primary antioxidant. It modulates glutamate and dopamine systems implicated in OCD, addiction, and bipolar disorder. RCTs have shown benefit for OCD compulsions, cannabis use disorder, and bipolar depression. Typical dose: 1,200–2,400 mg/day. Generally well-tolerated; GI upset is the main side effect.

Best studied for: OCD (adjunct), addiction, bipolar depression